Enrolling Lupus Studies


Sponsor: UCB

Protocol Number: SL0043

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

Detailed Information: Here

To learn more or see if you qualify: Click Here